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0239 has tolerable toxicity. The acute Gr3+ esophageal toxicities were 
not correlated with V10, V20 and V40 possibly because of the small 
number of patients with esophagitis. Pts continue to be followed for the 
primary endpoint of 2-year survival.
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Background: Standard treatment for SCLC has not yet been precisely 
deﬁned. The modalities of chemotherapy may not be the same for all 
patients. There has been a growing interest in heparin since our ﬁrst 
phase III randomized study (Cancer 1994; 74:38-45). Radiotherapy 
must be associated in selected patients, but the results of published 
clinical trials are not predictive for general population outcomes. 
Retrospective, but exhaustive, data analysis from 239 patients treated 
from 1990 to 2002 in a single specialized center emphasized the need 
for optimized treatment.
Methods: 54 computerized clinical and therapeutic items were 
obtained for each patient for statistical analysis. Chemotherapy was 
administered to 235/239 patients: PCDE (cisplatin, cyclophosphamide, 
doxorubicin, etoposide) for 105, CDE for 71, PE (cisplatin or carbopla-
tin, etoposide) for 57, via the intravenous route every four weeks, ex-
cept for two elderly patients in whom chemotherapy was administered 
orally. Chemotherapy was limited to six cycles for complete respond-
ers. Subcutaneous heparin was administered at curative doses cover-
ing the ﬁrst two cycles for 131 patients; 108 did not received heparin 
including contraindications in 16 patients. Limited forms received 
alternating thoracic radiation between the second and ﬁfth chemo-
therapy cycles for 78 patients and concurrent radiotherapy following 
the second cycle for 15 patients. Prophylactic cranial radiation (PCR) 
was administered to 78 patients in complete response and, curative 
cranial radiation to 57 patients with initial or late cerebral metastasis. 
14 patients were operated (surgery systematically associated with three 
or four cycles of chemotherapy). Cases of relapse or progression almost 
received second- or third- line chemotherapy.
Results: are expressed in terms of 2-year survivals, which is much 
more relevant than median survival for this population composed of 
130 limited (l) and 109 extensive (e) forms, with a mean age of 61 
± 11 years, sex ratio 2.7 (73% men), with 226 smokers or ex-smok-
ers. Metastases at diagnosis were mainly located in liver (27%), brain 
(15%) and/or bone (14%). Two-years survival rates were: l forms: 31%, 
e-forms: 7%; PCDE with heparin: 33%, PCDE without heparin: 15%; 
PE with heparin: 27%, PE without heparin: 12%; CDE with heparin: 
2%, CDE without heparin: 4%. 27 patients with limited forms who 
received PCDE + heparin + thoracic radiotherapy + PCR had a 44.2 
(IC 95% = 24.7-62.1)% two-year survival. In a multivariate analysis, 
signiﬁcant prognostic factors were: disease extension: p < 0.0001 (HR 
= 1.945 [1.47-2.58]), patient age: p < 0.006 (HR = 1.03 [1.01-1.04]), 
heparin use: p < 0.018 (HR = 1.4 [1.06-1.91]) and inclusion in a clini-
cal research trial: p < 0.025 (HR = 1.4 [1.05-2.07]).
Conclusions: Although these results can be partially explained by 
obvious clinical bias, the important role of using a combination of all of 
the present modes of therapy in the best patients is demonstrated by the 
outstanding 2-year-survival of 44.2%. On subgroup analysis, PE cannot 
be considered to constitute standard ﬁrst-line chemotherapy. Heparin 
appears to play a very important role in this optimization. In contrast, 
the 7% 2-year survival rate for extensive forms is relatively good for 
such an exhaustive population, probably due to regular treatment of 
relapse. 
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Background: To improve the overall prognosis of limited-disease 
small cell lung cancer (LD-SCLC), we performed a phase II study of 
concurrent administration of irinotecan/cisplatin and thoracic radiation 
therapy (IP+RT) followed by two cycles of consolidation chemotherapy 
with irinotecan/cisplatin (IP).
Methods and Materials: Patients with previously-untreated, histologi-
cally proven LD-SCLC were enrolled in this study. IP+RT consisted of 
2 cycles of irinotecan 35 mg/m2 (days 1, 8 and 15) and cisplatin 60 mg/ 
m2 (day 1) with a 4 week interval. Thoracic radiation therapy of a total 
dose of 59.4 -63 Gy (1.8-2.0 Gy/fx, 5 days/week), was given concur-
rently with the ﬁrst and second chemotherapy cycles. After completion 
of IP+RT, patients without evidence of disease progression received 
an additional 2 cycles of consolidation chemotherapy with irinotecan 
60 mg/m2 (days 1, 8 and 15) and cisplatin 60 mg/m2 (day 1) every 4 
weeks.
Results: Of the 29 patients who started treatment, 25 (86%) completed 
IP+RT. The overall response rate was 88% (95% conﬁdence interval 
[CI], 75 to 100%) including 10 complete responses. Acute toxic effects 
were mainly myelosuppression, esophagitis and diarrhea. Two patients 
died of pneumonitis and sepsis. In one patient, pneumothorax preclud-
ing further therapy was developed during IP+RT. Of the 17 patients 
who went to consolidation phase, all patients completed 2 cycles of IP. 
With a median follow-up duration of 19 months, progression-free and 
overall survival was 8 months (95% CI, 3 to 12 months) and 14 months 
(95% CI, 7 to 21 months), respectively.
Conclusion: IP+RT followed by consolidation IP is an active and toler-
ated regimen for LD-SCLC.
